Subject(s)
Hypereosinophilic Syndrome/pathology , Leukemia/pathology , Leukemic Infiltration/diagnosis , Myocardium/pathology , Adult , Fatal Outcome , Heart/diagnostic imaging , Humans , Hypereosinophilic Syndrome/diagnosis , Hypereosinophilic Syndrome/genetics , Hypereosinophilic Syndrome/metabolism , Leukemia/diagnosis , Leukemia/genetics , Leukemia/metabolism , Leukemic Infiltration/diagnostic imaging , Leukemic Infiltration/drug therapy , Male , Oncogene Proteins, Fusion , Receptor, Platelet-Derived Growth Factor alpha , mRNA Cleavage and Polyadenylation FactorsABSTRACT
AIM: Study was aimed to assess the real-world costs of manual thrombectomy (MT) in selected ST-segment elevation myocardial infarction patients with intracoronary thrombus (IT). METHODS: Study group (IT+) comprised 51 patients with MT applied and control group (IT-) comprised 56 patients without IT who underwent angioplasty alone. Costs comprised hospital care and cost of disposable materials used during primary angioplasty. RESULTS: Complex management of patients with IT is more expensive, though allows to achieve clinical outcomes comparable to low-risk ST-segment elevation myocardial infarction patients without IT. CONCLUSION: A complex pharmaco-interventional strategy, with glycoprotein IIB/IIIA inhibitor and MT, though more expensive, may prove cost-effective.
